Capmatinib
| CAS No. | 1029712-80-8 |
|---|---|
| MDL No. | MFCD18633285 |
| MF | C23H17FN6O |
| MW | 412.40 |
| InChI Key | LIOLIMKSCNQPLV-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Capmatinib is an imidazotriazine derivative with 3-fluoro-4-(methylcarbamoyl)phenyl at position 2 and quinolin-6-ylmethyl at position 7. It is a c-Met receptor tyrosine kinase inhibitor used to treat non-small cell lung cancer with MET exon 14 skipping mutations. It functions as a c-Met tyrosine kinase inhibitor, antineoplastic agent, hepatotoxic agent, and apoptosis inducer. It belongs to quinolines, monofluorobenzenes, benzamides, secondary carboxamides, and imidazotriazines.
| CAS No. | 1029712-80-8 |
|---|---|
| Product Name | Capmatinib |
Biological Targets
MET
Associated Conditions
lung cancer·breast cancer·hepatocellular carcinoma·kidney cancer·non-small cell lung carcinoma·
* The information provided here is compiled from public sources and is for reference only.
